TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06234098: Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent S

Sponsor: Alyssum Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$942,480

Rescue Site Savings

+$628,320

Unlock Full NCT06234098 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06234098 Rescue Dossier →